Eli Lilly and Co
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill […]
Read More
This pharma stock just got whacked — there’s still a major catalyst ahead
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks were climbing on Thursday led by semiconductors and AI-related names. Taiwan Semiconductor rallied more than 5% after reporting strong fourth quarter results and forecasting higher […]
Read More
Stocks making the biggest moves midday: Morgan Stanley, Coinbase, Taiwan Semi, Eli Lilly & more
Here are some of the names making big moves in midday trading. Eli Lilly — Shares of the weight loss drugmaker fell nearly 4% after Reuters reported that a Food and Drug Administration decision on its obesity pill would be delayed until April 10. The drug had been granted an expedited review under a Trump […]
Read More
Airlines to save big money on fuel as new weight loss pills gain popularity, Wall Street says
Celsopupo | Istock | Getty Images Wall Street is finding an unexpected beneficiary of America’s weight loss boom: airlines. With the first GLP-1 weight loss drug now available in pill form, analysts at Jefferies say broad adoption across society could quietly lower fuel bills — airlines’ single largest cost — and lift earnings for the […]
Read More
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]
Read More
The market’s Powell reaction, JPMorgan earnings, Siri’s AI upgrade and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. Nothing quite says the holidays are over like the beginning of a new corporate earnings season. Stock futures are ticking lower this morning following a winning day. Here are five key things investors need to know to start the trading […]
Read More
Stocks making the biggest moves midday: Citigroup, Abercrombie, Vistra, Duolingo and more
Check out some of the companies making the biggest moves in midday trading. Bank stocks — The group fell broadly after President Donald Trump called for credit card rates to be capped at 10% for one year . Capital One slid 6%, Synchrony Financial tumbled 8% and Citigroup dropped 3%. Bank of America , Wells […]
Read More
Powell’s criminal investigation, Google’s AI shopping push, Boeing deliveries and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Monday. I find myself at an impasse trying to decide what to write in this intro. As someone who’s committed to their skincare routine, I should write about this story on the latest men’s beauty trend. But as a Michigan native, […]
Read More
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]
Read More